GLP-1/GIP/glucagon triagonist potentially as effective as bariatric surgery for men and women.doi:10.1016/j.molmet.2017.02.002Jall, SigridSachs, StephanClemmensen, ChristofferFinan, BrianNeff, FraukeDiMarchi, Richard D.Tsch?p, Matthias H.
1、Jastreboff AM. et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” (2023) N Engl J Med. DOI: 10.1056/NEJMoa2301972; 2、Potent body weight loss, and therapeutic efficacy in a NASH animal...
a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist的文章,研究人员开发了一种靶向GLP-1、GCG和GIP受体的合成肽激动剂SAR441255,在动物模型中显示出优于双重GLP-1/GCG受体激动剂的
GLP-1及其类似物 胰高血糖素样肽(Glucagon-Like Peptide,GLP-1)是由肠道分泌的一种内源性肽类激素,促进胰岛素分泌并抑制胰高血糖素的分泌。胰高血糖素样肽-1受体激动剂(Glucagon-Like Peptide-1 Receptor Agonist,GLP-1RA )是GLP-1经结构修饰所得的GLP-1类似物,提高体内活性GLP-1水平,降低血糖。 上游制备工...
作者: 3靶点新药,GLP-1/GIP/Glucagon Receptor Tri-Agonist
1 爆火的 GLP-1 GLP-1(Glucagon-like peptide-1)是一种主要由肠道 L 细胞分泌的肠促胰素，可以...
近日,来自德国Integrated Drug Discovery的Martin Bossart团队和德国TA Diabetes的Anish Konkar团队在Cell Metabolism杂志上合作发表了一篇题为Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist的文章,研究人员开发了一种靶向GLP-1、GCG和GIP...
[1]Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/GIP/Glucagon tri-agonist (HM15211). EASD 2017. [2]LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinica...
在临床前模型中,降低三种受体活性导致体重减轻的效果比任何双受体激动剂都要显著[1]。最近,首次报道了一种三激动剂的在病人中的治疗结果[2]。 在Tamer Coskun等人2022年发表的文章《LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery ...
GLP-1 (Glucagon-like peptide-1) 是一种主要由肠道 L 细胞分泌的肠促胰素,可以激活 GLP-1 受体 (GLP-1R),以葡萄糖浓度依赖的方式促进胰岛素释放、抑制胰高血糖素分泌,从而达到降低血糖、减肥等作用[4][5]。 图1. GLP-1 对胰腺及其它组织的生理作用[6]。 营养摄入会刺激 GLP-1 的分泌,GLP-1 通过与...